Sage Therapeutics Stock News

Novavax's prospects in the coronavirus vaccine market look dim. Sage Therapeutics' recent regulatory news was a major blow to its prospects.

Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder.

Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69.

Sage Therapeutics, Inc. (NASDAQ:SAGE ) Business Update Call August 8, 2023 8:00 PM ET Company Participants Ashley Kaplowitz - Investor Relations Barry Greene - Chief Executive Officer Laura Gault - Ch

The U.S. FDA didn't approve zuranolone in treating major depressive disorder. However, the FDA did approve the drug in treating postpartum depression.

The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.

Sage Therapeutics (NASDAQ: SAGE ) stock isn't doing the best on Monday after the FDA weighed in on the biopharmaceutical company's depression drug zuranolone. According to Sage Therapeutics, it's unha

Sage stock plummeted Monday after the FDA approved its drug, Zurzuvae, in postpartum depression, but not major depressive disorder.

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.68 per share versus the Zacks Consensus Estimate of a loss of $2.53. This compares to loss of $2.13 per share a year ago.

Sage Therapeutics Inc.'s stock SAGE cratered 49% in premarket trade Monday, on disappointment that the U.S. regulator approved its zuranolone treatment for postpartum depression, but not for major dep

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a l

The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression.

The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill for two common forms of depression, paving the way for patients to get a faster-acting therapy to treat

Biogen's CEO downplayed the ongoing regulatory review for a Sage-partnered depression drug. The FDA is scheduled to hand down its decision by Aug. 5.

Sage Therapeutics, Inc. should find out in August whether its drug targeting major depressive disorder and postpartum depression, zuranolone, will be approved. Zuranolone is being co-developed with Bi